Identification

Generic Name
2,5-Dimethoxy-4-ethylamphetamine
DrugBank Accession Number
DB01467
Background

Not Available

Type
Small Molecule
Groups
Experimental, Illicit
Structure
Thumb
Weight
Average: 223.3113
Monoisotopic: 223.157228921
Chemical Formula
C13H21NO2
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Abaloparatide.
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
AceclofenacThe risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Acemetacin.
AcetazolamideAcetazolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
AcetophenazineAcetophenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 2,5-Dimethoxy-4-ethylamphetamine.
AclidiniumThe risk or severity of Tachycardia can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Aclidinium.
Acrivastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Acrivastine.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Alkyl aryl ether / Amine / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Dimethoxybenzene / Ether / Hydrocarbon derivative / Methoxybenzene
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
9SK6K682UL
CAS number
22004-32-6
InChI Key
HXJKWPGVENNMCC-UHFFFAOYSA-N
InChI
InChI=1S/C13H21NO2/c1-5-10-7-13(16-4)11(6-9(2)14)8-12(10)15-3/h7-9H,5-6,14H2,1-4H3
IUPAC Name
1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
SMILES
CCC1=CC(OC)=C(CC(C)N)C=C1OC

References

General References
Not Available
PubChem Compound
27402
PubChem Substance
46504746
ChemSpider
25499
BindingDB
81965
ChEMBL
CHEMBL8224
Wikipedia
2,5-Dimethoxy-4-ethylamphetamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.81HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.413 mg/mLALOGPS
logP2.71ALOGPS
logP2.45ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity66.27 m3·mol-1ChemAxon
Polarizability26.07 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9187
Caco-2 permeable+0.7659
P-glycoprotein substrateNon-substrate0.6693
P-glycoprotein inhibitor INon-inhibitor0.7698
P-glycoprotein inhibitor IINon-inhibitor0.9743
Renal organic cation transporterNon-inhibitor0.8405
CYP450 2C9 substrateNon-substrate0.857
CYP450 2D6 substrateSubstrate0.7859
CYP450 3A4 substrateNon-substrate0.5212
CYP450 1A2 substrateInhibitor0.7137
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorInhibitor0.7927
CYP450 2C19 inhibitorNon-inhibitor0.8757
CYP450 3A4 inhibitorNon-inhibitor0.9168
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6931
Ames testNon AMES toxic0.6594
CarcinogenicityNon-carcinogens0.7386
BiodegradationNot ready biodegradable0.8571
Rat acute toxicity3.0939 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9017
hERG inhibition (predictor II)Non-inhibitor0.6282
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at July 31, 2007 13:09 / Updated at June 12, 2020 16:51